ENTERA BIO LTD. Deferred Income Tax Expense (Benefit)
ENTERA BIO LTD. (ENTX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-27
- ENTERA BIO LTD. deferred income tax expense (benefit) for the quarter ending 2024-12-31 was $14.00K.
- ENTERA BIO LTD. deferred income tax expense (benefit) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ENTERA BIO LTD. deferred income tax expense (benefit) for the quarter ending 2023-09-30 was $29.00K, a 86.45% decline year-over-year.
- ENTERA BIO LTD. deferred income tax expense (benefit) for the quarter ending 2023-06-30 was $0.00.
- ENTERA BIO LTD. deferred income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ENTERA BIO LTD. deferred income tax expense (benefit) for fiscal 2024 was $14.00K, a 51.72% decline from fiscal 2023.
- ENTERA BIO LTD. deferred income tax expense (benefit) for fiscal 2023 was $29.00K, a 83.33% decline from fiscal 2022.
- ENTERA BIO LTD. deferred income tax expense (benefit) for fiscal 2022 was $174.00K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | |||
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $14.00K 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $29.00K derived: sum of 2 quarters · filed 2025-03-28 | $29.00K derived: sum of 3 quarters · filed 2025-03-28 | $29.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $29.00K derived: sum of 2 quarters · filed 2024-11-08 | $29.00K 10-Q · filed 2024-11-08 | $52.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $23.00K derived: sum of 3 quarters · filed 2024-03-08 | $237.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-05 | $23.00K derived: sum of 2 quarters · filed 2024-03-08 | $237.00K derived: sum of 3 quarters · filed 2024-03-08 | $207.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $237.00K derived: sum of 2 quarters · filed 2024-03-08 | $207.00K derived: sum of 3 quarters · filed 2024-03-08 | $174.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $184.00K derived: sum of 2 quarters · filed 2023-11-14 | $151.00K 10-Q · filed 2023-11-14 | $100.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$63.00K 10-Q · filed 2023-08-11 | -$114.00K derived: sum of 3 quarters · filed 2023-08-11 | -$171.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$33.00K 10-Q · filed 2023-05-05 | -$84.00K derived: sum of 2 quarters · filed 2023-05-05 | -$141.00K derived: sum of 3 quarters · filed 2023-05-05 | -$198.00K derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$108.00K derived: sum of 2 quarters · filed 2023-03-31 | -$165.00K derived: sum of 3 quarters · filed 2023-03-31 | -$217.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$114.00K derived: sum of 2 quarters · filed 2022-11-10 | -$166.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$109.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$52.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |